UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 __________________________
 Form 10-K
 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2023
 or

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from to
 Commission file number 000-30195
 (Exact name of registrant as specified in its charter)

 Delaware

 51-6516897

 (State or other jurisdiction of
incorporation or organization)

 (I.R.S. Employer
Identification No.)

 Rodney Square North

 19890

 1100 North Market Street
 (Zip Code)

 Wilmington,
 DE

 (Address of principal
executive offices)

 (302) 651-1000
 (Registrant's telephone number, including area code)
 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class
 Trading Symbol(s)
 Name of each exchange on which registered

 None
 N/A
 N/A

 Securities registered pursuant to Section 12(g) of the Act:
 Beneficial interests in the MetLife Policyholder Trust
 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No
 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No
 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer
 o
 Accelerated filer
 o

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report.
 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
 As of March 22, 2024, 116,072,684 Trust Interests were outstanding. The Trust Interests are not transferable except in limited circumstances and have no market value.
 DOCUMENTS INCORPORATED BY REFERENCE: NONE

 Page

 Item 1.
 Business

 Item 1A.
 Risk Factors

 Item 1B.
 Unresolved Staff Comments

 Item 1C.
 Cybersecurity

 Item 2.
 Properties

 Item 3.
 Legal Proceedings

 Item 4.
 Mine Safety Disclosures

 Item 5.
 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item 6.
 Reserved

 Item 7.
 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A.
 Quantitative and Qualitative Disclosures About Market Risk

 Item 8.
 Financial Statements and Supplementary Data

 Item 9.
 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 Item 9A.
 Controls and Procedures

 Item 9B.
 Other Information

 Item 9C.
 Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 Item 10.
 Directors, Executive Officers and Corporate Governance

 Item 11.
 Executive Compensation

 Item 12.
 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13.
 Certain Relationships and Related Transactions, and Director Independence

 Item 14.
 Principal Accountant Fees and Services

 Item 15.
 Exhibits and Financial Statement Schedules

 Item 16.
 Form 10-K Summary

 Exhibit Index

 Signatures

 Note Regarding Forward-Looking Statements
 This Annual Report on Form 10-K of the MetLife Policyholder Trust (the "Trust"), including Management's Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as "anticipate," "are confident," "assume," "believe," "continue," "could," "estimate," "expect," "if," "intend," "likely," "may," "plan," "potential," "project," "should," "will," "would" and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, future performance, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.
 Many factors determine the Trust's results, and they involve unpredictable risks and uncertainties. The Trust's forward-looking statements depend on its assumptions, its expectations, and its understanding of the economic environment, but they may be inaccurate and may change. The Trust does not guarantee any future performance. The Trust's results could differ materially from those it expresses or implies in forward-looking statements. The risks, uncertainties and other factors identified in the Trust's and MetLife, Inc.'s filings with the U.S. Securities and Exchange Commission (the "SEC"), and others, may cause such differences. These factors include:
 (i)dependence upon MetLife, Inc. for the value of the Trust Shares (as defined herein);
 (ii)limited rights of Beneficiaries (as defined herein), including with respect to voting power over the Trust Shares;
 (iii)no existing trading market for the Trust Interests (as defined herein) and limited ability of Beneficiaries to transfer such Trust Interests;
 (iv)termination of the Trust at the discretion of MetLife, Inc., or otherwise pursuant to the terms of the Trust Agreement (as defined herein);
 (v)failure to protect confidentiality and integrity of data, including Beneficiary information, or other cybersecurity or disaster recovery failures; and
 (vi)litigation and regulatory investigations, including as a result of the appointment of a representative on behalf of certain Beneficiaries.
 The Trust does not undertake any obligation to publicly correct or update any forward-looking statement if it later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures the Trust or MetLife, Inc. makes on related subjects in subsequent reports to the SEC.
 Note Regarding Reliance on Statements in Our Contracts
 See "Exhibit Index — Note Regarding Reliance on Statements in Our Contracts" for information regarding agreements included as exhibits to this Annual Report on Form 10-K.

 Item 1. Business
 Overview
 The Trust was established under the Metropolitan Life Insurance Company ("Metropolitan Life") plan of reorganization (the "Plan") and pursuant to the MetLife Policyholder Trust Agreement, dated as of November 3, 1999, by and among Metropolitan Life, MetLife, Inc., Wilmington Trust Company (not in its individual capacity, but solely as trustee for the Trust, the "Trustee") and ChaseMellon Shareholder Services, L.L.C., as custodian (now known as Computershare Inc., the "Custodian"), as amended on November 8, 2001 (the "Trust Agreement"), in connection with the conversion of Metropolitan Life from a mutual life insurance company to a stock life insurance company. The Trust is a single-purpose trust that does not engage in any business or activity other than voting and holding the Trust Shares and certain closely related activities, such as distributing cash dividends and other distributions. The Trust has no employees. See "Financial Statements and Supplementary Data" for financial information about the Trust.
 Under the Plan and the Trust Agreement, each policyholder's membership interest was extinguished and certain eligible policyholders of Metropolitan Life (the "Trust Eligible Policyholders") received, in exchange for that interest, a number of interests in the Trust ("Trust Interests") equal to the number of shares of common stock of MetLife, Inc., par value $0.01 per share (the "Common Stock"), allocated to them in accordance with the Plan. The assets of the Trust consist principally of the shares of Common Stock issued to the Trust (the "Trust Shares") for the benefit of the Trust Eligible Policyholders and permitted transferees (collectively, the "Beneficiaries"). The Trust Shares are held in the name of the Trustee, on behalf of the Trust, which has legal title over the Trust Shares. The Beneficiaries do not have legal title to any part of the assets of the Trust. The Trust Interests represent undivided fractional interests in the Trust Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian. On April 7, 2000, the date of demutualization of Metropolitan Life, MetLife, Inc. distributed to the Trust 494,466,664 shares of Common Stock for the benefit of policyholders of Metropolitan Life. Beneficiaries may withdraw all, but generally not less than all, of their allocated shares of Common Stock from the Trust at any time by providing written notice to the Custodian.
 Withdrawals by Beneficiaries of Trust Shares, transactions by Beneficiaries under the Purchase and Sale Program (as defined below), and escheatment of unclaimed Trust Shares resulted in a net decrease in the number of Trust Shares from 123,606,156 at December 31, 2022 to 117,556,699 at December 31, 2023.
 A Trust Interest entitles the Beneficiary to certain rights, including the right to: (i) receive dividends distributed upon Trust Shares; (ii) have Trust Shares withdrawn from the Trust to be sold for cash through a purchase and sale program established by MetLife, Inc. pursuant to the Plan (the "Purchase and Sale Program"); (iii) deposit in the Trust additional shares of Common Stock purchased through the Purchase and Sale Program; (iv) withdraw Trust Shares; and (v) instruct the Trustee to vote the Trust Shares on certain matters, each as further described in and limited by the terms of the Trust Agreement. The Trustee has no beneficial interest in the Trust Shares.
 As a general rule, Beneficiaries are prohibited from selling, assigning, transferring, encumbering or granting any option or any other interest in their Trust Interests; however, Trust Interests may be transferred in certain limited circumstances. See "Risk Factors — There is no existing trading market for the Trust Interests and Beneficiaries may transfer their Trust Interests only in limited circumstances."
 In addition, if the Board of Directors of MetLife, Inc. (the "Board") determines, based on the advice of legal counsel, that there is, at any time, a material risk that the assets of the Trust may be characterized as "plan assets" under United States Department of Labor Reg. §2510.3-101, as amended, the Board may direct the Trustee to distribute to the Custodian, for distribution to one or more Beneficiaries, a number of Trust Shares (not to exceed the total number of such Beneficiaries' Trust Interests) as the Board may determine to be necessary or appropriate to ensure that the assets of the Trust will not be so characterized as "plan assets."
 A transferee of Trust Interests will become subject to the Trust Agreement. The Trust Interests are held in the name of the Custodian, which keeps a record of the Trust Interests of the Beneficiaries on a book-entry system maintained by the Custodian. The Trust Interests are not represented by certificates or other evidences of ownership.
 Purchase and Sale Program
 See Note 2 of the Notes to the Financial Statements for information regarding the Purchase and Sale Program.

 Beneficiary Voting Rights
 See Note 4 of the Notes to the Financial Statements for information regarding the manner in which the Trustee may vote, assent or consent the Trust Shares at all times during the term of the Trust (i) on all matters brought for a vote before the stockholders of MetLife, Inc.; and (ii) on all Beneficiary Consent Matters (as defined below).
 A "Beneficiary Consent Matter" is a matter presented to stockholders of MetLife, Inc. concerning the following:
 (i)subject to certain conditions, a contested election of directors or the removal of a director;
 (ii)a merger or consolidation, a sale, lease or exchange of all or substantially all of the property or assets or a recapitalization or dissolution of MetLife, Inc., if it requires a vote of stockholders under applicable Delaware law;
 (iii)any transaction that would result in an exchange or conversion of Trust Shares for cash, securities or other property; and
 (iv)proposals submitted to stockholders requiring the Board to amend MetLife, Inc.'s stockholder rights plan, or redeem rights under that plan, other than a proposal with respect to which MetLife, Inc. has received advice of nationally-recognized legal counsel to the effect that the proposal is not a proper subject for stockholder action under Delaware law. MetLife, Inc. does not currently have a stockholder rights plan.
 Proxy solicitation materials, annual reports and information statements received by the Custodian in connection with any matter not involving a Beneficiary Consent Matter will be made available by MetLife, Inc. to Beneficiaries for their information on a website maintained by MetLife, Inc. or by mail upon request and at MetLife, Inc.'s expense, but voting instructions to the Trustee will not be solicited and, if instructions are received, they will not be binding on the Trustee.
 Distributions to Trust Beneficiaries
 See Note 1 of the Notes to the Financial Statements for information regarding distributions to Beneficiaries.
 Termination of the Trust
 See Note 1 of the Notes to the Financial Statements for information regarding the termination of the Trust.
 Pursuant to the Trust Agreement, the Trust is eligible to be terminated at MetLife, Inc.'s discretion, as the Trust Shares constitute less than 25% of the number of issued and outstanding shares of Common Stock. See "— Common Stock Transactions" and "Risk Factors — The Trust is terminable at any time at the discretion of MetLife, Inc." MetLife, Inc. has not advised the Trustee of any intention to voluntarily terminate the Trust.
 Common Stock Transactions
 The number of Trust Shares declined to 117,556,699 at December 31, 2023 as a result of withdrawals by Beneficiaries of Trust Shares, transactions by Beneficiaries under the Purchase and Sale Program and escheatment of unclaimed Trust Shares. The percentage of outstanding shares of Common Stock owned by the Trust increased from 15.9% at December 31, 2022 to 16.1% at December 31, 2023. See Note 1 to the Financial Statements for further information regarding Common Stock issuances and repurchases.
 In May 2023, MetLife, Inc. announced that the Board authorized a total of $4.0 billion of Common Stock repurchases. At December 31, 2023, MetLife, Inc. had $2.1 billion of Common Stock repurchases remaining under the authorizations. See Note 1 of the Notes to the Financial Statements.
 See also "— Restrictions on Payment of Common Stock Dividends to Trust Beneficiaries" for a description of restrictions that may also be applicable to MetLife, Inc.'s ability to repurchase its Common Stock.

 Amendments, Preemptive Rights and Expenses
 The Trust Agreement may be amended from time to time by the Trustee, the Custodian, MetLife, Inc. and Metropolitan Life, without the consent of any Beneficiary, to: (i) cure any ambiguity, correct or supplement any provision therein that may be inconsistent with any other provision therein, or to make any other provision with respect to matters or questions arising under the Trust Agreement, which will not be inconsistent with the other provisions of the Trust Agreement, provided that the action does not adversely affect the Trust Interests of the Beneficiaries; (ii) modify, eliminate or add to any provisions of the Trust Agreement to such extent as will be necessary to ensure that the Trust will be classified for United States federal income tax purposes as a grantor trust at all times or to ensure that the Trust will not be required to register as an investment company under the Investment Company Act of 1940, as amended; or (iii) reflect the effect of a merger or consolidation in which MetLife, Inc. is not the surviving corporation and the other company into which MetLife, Inc. is merged or consolidated assumes its obligations under the Trust Agreement. The Trust Agreement may also be amended or provisions thereof waived with the consent of Beneficiaries representing more than one-half of the Trust Interests, provided that no such amendment or waiver will, without the consent of each Beneficiary affected thereby, reduce the Trust Interests or otherwise eliminate or materially postpone the right of any Beneficiary to receive dividends or other distributions or to make elections under the Purchase and Sale Program or to withdraw Trust Shares.
 Beneficiaries will not have any preemptive rights with respect to the Trust Interests. There is no provision for any sinking fund with respect to the Trust Interests.
 The Trust Agreement provides that MetLife, Inc. shall pay, or reimburse directly, each of the Trustee and the Custodian for all costs and expenses relating to the Trust, in the case of the Trustee, and relating to the holding of Trust Interests, in the case of the Custodian, including, but not limited to, the fees and expenses as provided in the Trust Agreement. MetLife, Inc. pays the Trustee an annual fee of $50 thousand. MetLife, Inc. paid to the Trustee $21 thousand, $30 thousand and $38 thousand for out-of-pocket expenses for the years ended December 31, 2023, 2022 and 2021, respectively. MetLife, Inc. paid to the Trust's independent auditors $59 thousand for audit fees for each of the years ended December 31, 2023, 2022 and 2021. None of the aforementioned fees and expenses are included in the Trust's financial statements. MetLife, Inc. also provides the Trustee with certain management and administrative services.
 Restrictions on Payment of Common Stock Dividends to Trust Beneficiaries
 The declaration and payment of Common Stock dividends are subject to the discretion of the Board, and will depend on MetLife, Inc.'s financial condition, results of operations, cash requirements, future prospects, regulatory restrictions on the payment of dividends by MetLife, Inc.'s insurance subsidiaries and other factors deemed relevant by the Board. MetLife, Inc.'s preferred stock and junior subordinated debentures contain "dividend stopper" provisions under which MetLife, Inc. may not pay dividends on instruments junior to those instruments if payments have not been made on those instruments. Moreover, MetLife, Inc.'s Series A preferred stock and its junior subordinated debentures contain provisions that may limit the payment of dividends or interest on those instruments if MetLife, Inc. experiences financial stress. MetLife, Inc. may not be able to pay dividends if it does not receive sufficient funds from its operating subsidiaries.

 The table below presents Common Stock dividend declaration, record and payment dates, as well as per share and aggregate dividend amounts, applicable to the Trust Shares, for the years ended December 31, 2023 and 2022:

 Dividend

 Declaration Date
 Record Date
 Payment Date
 Per Share
 Aggregate

 (In millions)

 Year Ended December 31, 2023

 October 10, 2023
 November 9, 2023
 December 14, 2023
 $
 0.520
 $

 July 11, 2023
 August 8, 2023
 September 14, 2023
 0.520

 April 25, 2023
 May 9, 2023
 June 14, 2023
 0.520

 January 10, 2023
 February 7, 2023
 March 14, 2023
 0.500

 Total
 $
 2.060
 $

 Year Ended December 31, 2022

 October 11, 2022
 November 8, 2022
 December 14, 2022
 $
 0.500
 $

 July 11, 2022
 August 9, 2022
 September 14, 2022
 0.500

 April 26, 2022
 May 10, 2022
 June 14, 2022
 0.500

 January 10, 2022
 February 8, 2022
 March 14, 2022
 0.480

 Total
 $
 1.980
 $

 The Beneficiaries of the Trust are directed to MetLife, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2023 and the other filings of MetLife, Inc. under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for information regarding MetLife, Inc., including additional information regarding restrictions on MetLife, Inc.'s ability to pay dividends on and repurchase its Common Stock. See Metropolitan Life Insurance Company (1999 SEC No-Act. LEXIS 914) (Avail. Nov. 23, 1999). The Trustee does not control the operations or activities of MetLife, Inc. The Trustee relies on receiving information, reports and representations from MetLife, Inc. and the Custodian in the ordinary course of its business. In executing and submitting this report on behalf of the Trust, the Trustee has relied upon the accuracy of such reports and representations of the aforementioned entities.

 Item 1A. Risk Factors
 The Trust has limited resources and is dependent upon MetLife, Inc.
 The Trust is a single-purpose trust that does not engage in any business or activity other than voting and holding the Trust Shares and certain closely related activities, such as distributing cash dividends and other distributions. The assets of the Trust consist principally of the Trust Shares. As such, the Trust is exposed to equity market risk; any decline in the market price of Common Stock will adversely affect the value of the Trust Shares and, correspondingly, the Beneficiaries' Trust Interests. Beneficiaries of the Trust are directed to MetLife, Inc.'s Risk Factors set forth in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2023 and the other Exchange Act filings of MetLife, Inc. for information regarding certain risks related to MetLife, Inc. that may affect the value of the Trust Shares, including regulatory and other restrictions which may affect MetLife, Inc.'s ability to pay dividends on the Common Stock. See also "Quantitative and Qualitative Disclosures About Market Risk."
 Beneficiaries do not have legal title to any part of the Trust assets and have only certain limited rights.
 The Trust has legal title over the Trust Shares. The Trust Interests represent undivided fractional interests in the Trust Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian. A Trust Interest entitles the Beneficiary only to certain rights. See "Business — Overview" and Note 1 of the Notes to the Financial Statements. Voting instructions to the Trustee on any matter not involving a Beneficiary Consent Matter will not be solicited and, if instructions are received, they will not be binding on the Trustee. On all matters other than Beneficiary Consent Matters, the Trustee shall vote, assent or consent the Trust Shares in favor of and in opposition to such matter, or abstain from voting on such matter, in accordance with the recommendation given by the Board to its stockholders in respect of the matter, or, if no such recommendation is given, as directed by the Board.

 There is no existing trading market for the Trust Interests and Beneficiaries may transfer their Trust Interests only in limited circumstances.
 There is no existing trading market for the Trust Interests and the Trust Interests have no market value. Furthermore, Trust Interests may generally be transferred only in the following situations: (i) from the estate of a deceased Beneficiary to one or more beneficiaries taking by operation of law or pursuant to testamentary succession; (ii) to the spouse or issue of a Beneficiary or to an entity selected by a Beneficiary, provided that transfers to such entity are deductible for federal income, gift and estate tax purposes under §§170, 2055 and 2522 of the Internal Revenue Code of 1986, as amended, or to a trust established for the exclusive benefit of one or more of the following: (x) Beneficiaries, (y) individuals described in this clause (ii), or (z) entities described in this clause (ii); (iii) to a trust established to hold Trust Interests on behalf of an employee benefit plan; (iv) if the Beneficiary is not a natural person, by operation of law to the surviving entity upon the merger or consolidation of such Beneficiary into another entity, to the purchaser of substantially all the assets of such Beneficiary or to the appropriate persons upon the dissolution, termination or winding up of such Beneficiary; (v) by operation of law as a consequence of the bankruptcy or insolvency of such Beneficiary or the granting of relief to such Beneficiary under the Federal bankruptcy laws; or (vi) from a trust holding an insurance policy or annuity contract on behalf of the insured person under such policy or contract, to those persons to whom Trust Interests are required to be so transferred pursuant to the terms of such trust.
 The Trust is terminable at any time at the discretion of MetLife, Inc.
 The Trust Agreement provides that MetLife, Inc. may terminate the Trust once the percentage of outstanding shares of Common Stock held in the Trust falls to 25% of the number of issued and outstanding shares of Common Stock. The winding up of the Trust must commence 90 days after the date on which the Trustee receives written notice from MetLife, Inc. that the number of Trust Shares is 10% or less of the number of issued and outstanding shares of Common Stock. Withdrawals by Beneficiaries of Trust Shares, sales by Beneficiaries of Trust Shares under the Purchase and Sale Program and escheatment of unclaimed Trust Shares, as well as issuances of Common Stock by MetLife, Inc. will result in a decrease of the percentage of outstanding shares of Common Stock held in the Trust; purchases by Beneficiaries of Trust Shares under the Purchase and Sale Program, and repurchases of Common Stock by MetLife Inc. will result in an increase of such percentage. At February 8, 2024, the number of Trust Shares represented 16.2% of the number of issued and outstanding shares of Common Stock and, thus, the Trust may be terminated at the discretion of MetLife, Inc.
 The Custodian or any of its vendors may fail to protect the confidentiality and integrity of data, including Beneficiary confidential information, as a result of a failure in any of their respective cybersecurity or other information security systems, or disaster recovery plans, and any such failure may also adversely affect the Trust's operations.
 The operation of the Trust is highly dependent on the effective and proper functioning of the information systems of the Custodian and its vendors. Any of these systems may be impacted by computer viruses or other malicious codes, unauthorized or fraudulent access, human errors, cyberattacks or other penetrations. A failure in the security of such systems, including those of internal or external vendors, or the confidential information stored thereon, or the use by the Custodian's employees or agents of unauthorized tools, software or other technology to communicate with their customers or business counterparties, may adversely affect the Trust's ability to operate and may result in regulatory enforcement action and litigation.
 The Custodian or any of its vendors may suffer disasters such as a natural catastrophe, epidemic, pandemic, industrial accident, blackout, war, terrorist attack, computer virus, ransomware or cyberattack, or other breaches or incidents affecting cybersecurity and information security systems. Globally, the frequency, severity and sophistication of cybersecurity incidents has increased, and these trends may continue. Efforts to minimize the risk of cyber incidents and to protect information technology may be insufficient to prevent material break-ins, attacks, fraud, security breaches or other unauthorized access to the systems of the Custodian and its vendors, including as a result of software code that contains vulnerabilities that are unknown that may increase the potential of cyber-attacks or unauthorized access. Such incidents may not be timely detected. There is no assurance that the security measures of the Custodian or any of its vendors, including information security policies, administrative, technical and physical controls and other actions designed as preventative, will provide fully effective protection from such events.
 In connection with the Trust's operations, personal, confidential and proprietary information is routinely transmitted, received and stored by electronic means. Failure to keep such information confidential and secure may result in the intentional or unintentional disclosure or misuse of confidential information, as well as others' misappropriation of such confidential information which could result in significant legal and regulatory liability and expenses.
 Information security and disaster recovery systems of the Custodian may be insufficient to safeguard the Trust's information, particularly if computer-based data processing, transmission, storage and retrieval systems are affected, and

 confidentiality, integrity or availability of valuable data are adversely impacted. The ability of the Custodian to conduct business effectively and maintain the security, integrity, confidentiality or privacy of sensitive data could be severely compromised if key personnel are unavailable, or if vendors' ability to provide goods and services or to perform their job responsibilities is impaired by a disaster, each of which could adversely affect the Trust's operations. The Custodian may not carry insurance sufficient to protect the Trust from all losses that may result from such interruptions, and any insurance for liability, operational and other risks may become less readily available or more expensive in the future.
 Regulators' or others' scrutiny of cybersecurity, including new laws or regulations, could increase compliance costs and operational burdens, especially as regulatory and legislative focus on cybersecurity matters intensifies, which could lead to more enforcement actions of such laws or regulations. Regulators, Trust Beneficiaries or others may act against the Trust for any cybersecurity failures. Continuous technological evaluations and enhancements, including changes designed to update protective measures, may increase the risk of a breach or gap in security measures. Any of these could adversely impact the processing of transactions, including those under the Purchase and Sale Program, as well as the confidential proprietary and other information processed and stored in, and transmitted through such computer systems and networks or otherwise cause interruptions or malfunctions in the operations of the Trust, which could expose the Trust to litigation and result in increased costs, regulatory investigations and penalties and/or Beneficiary dissatisfaction. Moreover, all of the documents and records in the information storage systems used by the Custodian, whether electronic or physical, may not be reliably accessible. Compliance with laws on, or regulators' scrutiny of, the use, collection, management, or transfer of data and other privacy practices could result in higher costs.
 The Custodian has an increasing challenge of attracting and retaining highly qualified personnel to combat security threats. Continuous technological evaluations and enhancements, including changes designed to update protective measures, may increase the risk of a breach or gap in security. The Trust may incur higher costs to comply with laws on, or regulators' scrutiny of, the use, collection, management or transfer of data and other privacy practices. There can be no assurance that enhancements to the cybersecurity and information security systems of the Custodian will be effective in preventing or limiting the impact of future cybersecurity incidents.
 Litigation may result in adverse results or other consequences; a representative may be appointed for certain Beneficiaries in legal proceedings.
 It is possible that claims, litigation, unasserted claims probable of assertion, investigations and proceedings may be commenced in the future, and the Trust could become subject to investigations and have lawsuits filed or enforcement actions initiated against it which could adversely affect the results of the Trust or have other consequences.
 In any lawsuit or other legal proceeding involving the Trust Interests, a representative may be appointed to represent Beneficiaries who do not have the legal capacity to represent themselves or whose addresses are unknown. The outcome of the lawsuit or other legal proceeding will be binding on Beneficiaries for whom the representative was appointed in the lawsuit or other proceeding.

 Item 1B. Unresolved Staff Comments

 Item 1C. Cybersecurity
 Pursuant to the Trust Agreement and other operational agreements among the parties, the Custodian is responsible for implementing and maintaining measures to protect the systems on which the Trust's operational data is stored and processed, including third party systems, and the information security risks associated with the same. There are no directors, executive officers or other employees of the Trust.
 The Custodian is required by contract to ensure it has implemented, and requires its critical vendors to implement, cybersecurity and data protection measures that are reasonable and appropriate for the operation of, and enterprise risks facing, the Custodian, which measures also include processes to assess, identify and manage risks from cybersecurity threats that may materially affect the Trust. Such contract requires the Custodian to inform MetLife, Inc., of any actual or reasonably suspected data security incident, including any loss, compromise, unauthorized use, access, or disclosure of information provided to it as contemplated thereunder.
 During the period covered by this report, the Trust has not identified risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect the Trust, including its results of operations or financial condition. For further discussion of risks related to cybersecurity, see "Risk Factors —The Custodian or any of its vendors may fail to protect the confidentiality and integrity of data, including

 Beneficiary confidential information, as a result of a failure in any of their respective cybersecurity or other information security systems, or disaster recovery plans, and any such failure may also adversely affect the Trust's operations."

 Item 2. Properties

 Item 3. Legal Proceedings
 None.

 Item 4. Mine Safety Disclosures

 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
 No public market exists for the Trust Interests.

 Item 6. Reserved

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
 This discussion should be read in conjunction with "Note Regarding Forward-Looking Statements," "Risk Factors," "Quantitative and Qualitative Disclosures About Market Risk" and the Trust's financial statements included elsewhere herein.
 This Management's Discussion and Analysis of Financial Condition and Results of Operations may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. See "Note Regarding Forward-Looking Statements" for cautionary language regarding forward-looking statements.
 For information relating to the Trust's financial condition and results of operations as of and for the year ended December 31, 2021, as well as for the year ended December 31, 2022 compared with the year ended December 31, 2021, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Trust's Annual Report on Form 10-K for the year ended December 31, 2022.
 Executive Summary
 The Trust was established under the Plan and pursuant to the Trust Agreement, in connection with the conversion of Metropolitan Life from a mutual life insurance company to a stock life insurance company. The Trust is a single-purpose trust that does not engage in any business or activity other than voting and holding the Trust Shares and certain closely related activities, such as distributing cash dividends and other distributions. See "Business — Overview" and Note 2 of the Notes to the Financial Statements.
 The number of Trust Interests outstanding at December 31, 2023 and 2022 was 117,556,699 and 123,606,156, respectively. The decrease of 6,049,457 in the number of Trust Interests is primarily attributable to Trust Interests redeemed, Trust Interests withdrawn and Trust Interests escheated. Net assets of the Trust consist solely of Trust Shares which will increase or decrease depending upon, among other things, the movement of Trust Shares into or out of the Trust as directed by the Beneficiaries.
 Results of Operations
 Discussion of Results
 Year ended December 31, 2023 compared with the year ended December 31, 2022
 Net assets in the Trust decreased $1.2 billion, or 13%, to $7.8 billion at December 31, 2023 from $8.9 billion at December 31, 2022. This decrease was primarily due to (i) a decrease in net unrealized investment gains on the Trust Shares; (ii) net activity under the Purchase and Sale Program; (iii) the impact of withdrawals of Trust Shares by Beneficiaries from the Trust; and (iv) the impact of escheatment of unclaimed cash and Trust Shares. Net unrealized investment gains, which represent the difference between the estimated fair value and the cost basis of the Trust Shares, decreased $1.1 billion from the prior year. A net reduction of 6,049,457 Trust Interests resulted from (i) a net decrease of 3,761,334 Trust Interests in connection with redemptions and issuances under the Purchase and Sale Program, (ii) a decrease of 1,284,993 Trust Interests due to withdrawals of Trust Shares by Beneficiaries from the Trust, and (iii) a decrease of 1,003,130 Trust Interests due to escheatment of Trust Shares. The net reduction of Trust Interests as a result of activity through the Purchase and Sale Program, withdrawals of Trust Shares by Beneficiaries from the Trust and escheatment of unclaimed cash and Trust Shares decreased net assets for the year ended December 31, 2023 by $47 million, $16 million and $13 million, respectively. Net investment income of $249 million, which consisted of Common Stock dividends received from MetLife, Inc., and net realized investment gains of $186 million recognized on the sale of Trust Shares through the Purchase and Sale Program, were fully allocated to Beneficiaries.
 Subsequent Events
 Common Stock Dividends
 On January 9, 2024, the Board declared a first quarter 2024 Common Stock dividend of $0.52 per share payable on March 14, 2024 to shareholders of record as of February 6, 2024. The aggregate dividend payment to Beneficiaries was $61 million.

 Item 7A. Quantitative and Qualitative Disclosures About Market Risk
 The Trust's investments are in equity securities, all of which are exposed to equity market risk. The market valuation of equity securities can fluctuate in response to political, market and economic developments and affect a single issuer, issuers within an industry, an economic sector, a geographic region, or the market as a whole. In the short-term, equity prices can fluctuate dramatically in response to these developments. Changes in other market factors, such as interest rates and foreign exchange rates, will also impact the value of the Trust's investments to the extent they impact the market value of the Trust Shares held. As the Trust's holdings in equity securities can only be comprised of Common Stock under the terms of the Trust Agreement, the Trust is unable to diversify its holdings to mute price fluctuations, the effects of which inure to the Beneficiaries.

 Item 8. Financial Statements and Supplementary Data
 Index to Financial Statements and Notes

 Page

 Report of Independent Registered Public Accounting Firm (PCAOB ID 34)

 Financial Statements at December 31, 2023 and 2022 and for the Years Ended December 31, 2023, 2022 and 2021:

 Statements of Assets and Liabilities

 Statements of Operations

 Statements of Changes in Net Assets

 Notes to the Financial Statements

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 MetLife Policyholder Trust:
 Opinion on the Financial Statements
 We have audited the accompanying statements of assets and liabilities of the MetLife Policyholder Trust (the "Trust") as of December 31, 2023 and 2022, the related statements of operations and changes in net assets, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Trust as of December 31, 2023 and 2022, and the results of its operations and changes in net assets for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
 Basis for Opinion
 These financial statements are the responsibility of the Trust's management. Our responsibility is to express an opinion on the Trust's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Trust in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Trust is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control over financial reporting. Accordingly, we express no such opinion.
 Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 Critical Audit Matters
 Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 /s/ Deloitte & Touche LLP
 New York, New York
 March 27, 2024

 We have served as the Trust's auditor since 2000.

 Statements of Assets and Liabilities
 December 31, 2023 and 2022
 (In thousands, except Trust Interests and per Trust Interest amounts)

 2023
 2022

 Assets

 Equity securities, at estimated fair value (cost: $ 1,570,835 and $ 1,647,281 at December 31, 2023 and 2022, respectively)

 $
 7,774,025
 $

 Cash

 Receivable for equity securities sold
 2,701
 2,381

 Dividends receivable from MetLife, Inc.
 79,452
 79,964

 Total assets
 7,856,180
 9,027,725

 Liabilities

 Payable for equity securities purchased

 Payable for Trust Interests redeemed
 2,701
 2,381

 Dividends payable to Trust Beneficiaries
 79,452
 79,964

 Total liabilities
 82,155
 82,347

 Net assets
 $
 7,774,025
 $

 Net assets consist of:

 Trust Interests
 $
 1,570,835
 $
 1,647,281

 Net unrealized investment gains
 6,203,190
 7,298,097

 Net assets available for Trust Interests outstanding

 $
 7,774,025
 $

 Net asset value per Trust Interest of ($ 7,774,025 / 117,556,699) and ($ 8,945,378 / 123,606,156) at December 31, 2023 and 2022, respectively

 $
 66.13
 $
 72.37

 See accompanying notes to the financial statements.

 Statements of Operations
 Years Ended December 31, 2023, 2022 and 2021
 (In thousands)

 2023
 2022
 2021

 Net investment income
 $
 248,542
 $
 250,340
 $
 252,180

 Net investment gains (losses):

 Net realized investment gains
 185,694
 198,532
 201,959

 Change in net unrealized investment gains
 ( 1,094,907)
 938,381
 1,778,835

 Total net investment gains (losses)
 ( 909,213)
 1,136,913
 1,980,794

 Net increase (decrease) in net assets resulting from operations
 $
 ( 660,671)
 $
 1,387,253
 $
 2,232,974

 See accompanying notes to the financial statements.

 Statements of Changes in Net Assets
 Years Ended December 31, 2023, 2022 and 2021
 (In thousands, except Trust Interests amounts)

 2023
 2022
 2021

 Operations

 Net investment income
 $
 248,542
 $
 250,340
 $
 252,180

 Net realized investment gains
 185,694
 198,532
 201,959

 Change in net unrealized investment gains
 ( 1,094,907)
 938,381
 1,778,835

 Net increase (decrease) in net assets resulting from operations

 ( 660,671)
 1,387,253
 2,232,974

 Distributions to holders of Trust Interests

 From net investment income
 ( 248,542)
 ( 250,340)
 ( 252,180)

 From net realized investment gains
 ( 185,694)
 ( 198,532)
 ( 201,959)

 Decrease in net assets resulting from distributions
 ( 434,236)
 ( 448,872)
 ( 454,139)

 Trust Interests transactions

 Cost of Trust Interests issued
 1,045
 1,467
 1,916

 Cost of Trust Interests redeemed
 ( 48,264)
 ( 46,461)
 ( 54,071)

 Cost of Trust Interests withdrawn
 ( 16,414)
 ( 14,992)
 ( 18,266)

 Cost of Trust Interests escheated
 ( 12,813)
 ( 11,196)
 ( 13,486)

 Net decrease in net assets resulting from Trust Interests transactions

 ( 76,446)
 ( 71,182)
 ( 83,907)

 Total increase (decrease) in net assets
 ( 1,171,353)
 867,199
 1,694,928

 Net assets

 Beginning of year
 8,078,179
 6,383,251

 End of year
 $
 7,774,025
 $
 $
 8,078,179

 Other information

 Trust Interests rollforward:

 Balance at January 1,
 123,606,156
 129,271,548
 135,958,492

 Trust Interests issued
 17,194
 22,259
 31,979

 Trust Interests redeemed
 ( 3,778,528)
 ( 3,637,360)
 ( 4,233,165)

 Trust Interests withdrawn
 ( 1,284,993)
 ( 1,173,740)
 ( 1,429,984)

 Trust Interests escheated
 ( 1,003,130)
 ( 876,551)
 ( 1,055,774)

 Balance at December 31,
 117,556,699
 123,606,156
 129,271,548

 See accompanying notes to the financial statements.

 Notes to the Financial Statements

 1. Significant Accounting Policies
 Description of the Trust
 The MetLife Policyholder Trust (the "Trust") was established under the Metropolitan Life Insurance Company ("Metropolitan Life") plan of reorganization (the "Plan") and pursuant to the MetLife Policyholder Trust Agreement, dated as of November 3, 1999, by and among Metropolitan Life, MetLife, Inc., Wilmington Trust Company (not in its individual capacity, but solely as trustee for the Trust, the "Trustee") and ChaseMellon Shareholder Services, L.L.C., as custodian (now known as Computershare Inc., the "Custodian") (as amended on November 8, 2001, the "Trust Agreement"), in connection with the conversion of Metropolitan Life from a mutual life insurance company to a stock life insurance company. The Trust is a single-purpose trust that does not engage in any business or activity other than voting and holding the Trust Shares (as defined below) and certain closely related activities, such as distributing cash dividends and other distributions. The Trust has no employees.
 Under the Plan and the Trust Agreement, each policyholder's membership interest was extinguished and certain eligible policyholders of Metropolitan Life (the "Trust Eligible Policyholders") received, in exchange for that interest, a number of interests in the Trust ("Trust Interests") equal to the number of shares of common stock of MetLife, Inc., par value $ 0.01 per share (the "Common Stock"), allocated to them in accordance with the Plan. The assets of the Trust consist principally of the shares of Common Stock issued to the Trust (the "Trust Shares") for the benefit of the Trust Eligible Policyholders and permitted transferees (collectively, the "Beneficiaries"). The Trust Shares are held in the name of the Trustee, on behalf of the Trust, which has legal title over the Trust Shares. The Beneficiaries do not have legal title to any part of the assets of the Trust. The Trust Interests represent undivided fractional interests in the Trust Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian. On April 7, 2000, the date of demutualization of Metropolitan Life, MetLife, Inc. distributed to the Trust 494,466,664 shares of Common Stock for the benefit of policyholders of Metropolitan Life.
 Withdrawals by Beneficiaries of Trust Shares, transactions by Beneficiaries under the Purchase and Sale Program (as defined below), and escheatment of unclaimed Trust Shares resulted in a net decrease in the number of Trust Shares from 123,606,156 at December 31, 2022 to 117,556,699 at December 31, 2023. See "— Termination of the Trust."
 A Trust Interest entitles the Beneficiary to certain rights, including the right to: (i) receive dividends distributed upon Trust Shares; (ii) have Trust Shares withdrawn from the Trust to be sold for cash through a purchase and sale program established by MetLife, Inc. pursuant to the Plan (the "Purchase and Sale Program"); (iii) deposit in the Trust additional shares of Common Stock purchased through the Purchase and Sale Program; (iv) withdraw Trust Shares, including for exchange in connection with an exchange offer for Common Stock; and (v) instruct the Trustee to vote the Trust Shares on certain matters, each as further described in and limited by the terms of the Trust Agreement. The Trustee has no beneficial interest in the Trust Shares.
 The Trust accounts for Trust Interests transactions as follows:
 (i)Dividends distributed upon Trust Shares are recorded as both net investment income when earned and distributions to holders of Trust Interests when due;
 (ii)Gains (losses) on Trust Shares withdrawn from the Trust and sold for cash through the Purchase and Sale Program are recorded as net realized investment gains (losses) relating to distributions to holders of Trust Interests and represent the difference between the sales proceeds and the cost basis of such shares. The cost basis of such shares is recorded as a reduction in Trust Interests at cost and classified as Trust Interests redeemed;
 (iii)Deposits into the Trust of additional shares of Common Stock purchased through the Purchase and Sale Program are recorded at acquisition cost and classified as Trust Interests issued;
 (iv)Withdrawals of Trust Shares are recorded as reductions in Trust Interests at cost and classified as Trust Interests withdrawn; and
 (v)Escheatment of unclaimed Trust Shares is recorded as a reduction in Trust Interests at cost and classified as Trust Interests escheated.

 Notes to the Financial Statements — (continued)
 1. Significant Accounting Policies (continued)

 The Trust Agreement provides that MetLife, Inc. shall pay, or reimburse directly, each of the Trustee and the Custodian for, all costs and expenses relating to the Trust, in the case of the Trustee, and relating to the holding of Trust Interests, in the case of the Custodian, including, but not limited to, the fees and expenses as provided in the Trust Agreement. MetLife, Inc. pays the Trustee an annual fee of $ 50 thousand. MetLife, Inc. paid to the Trustee $ 21 thousand, $ 30 thousand and $ 38 thousand for out-of-pocket expenses for the years ended December 31, 2023, 2022 and 2021, respectively. MetLife, Inc. paid to the Trust's independent auditors $ 59 thousand for audit fees for each of the years ended December 31, 2023, 2022 and 2021. None of the aforementioned fees and expenses is included in the Trust's financial statements. MetLife, Inc. also provides the Trustee with certain management and administrative services.
 The accompanying financial statements of the Trust have been prepared in conformity with accounting principles generally accepted in the United States of America.
 Termination of the Trust
 The Trust will be terminated on the first to occur (each, a "Termination Event") of (i) the 90th day after the date on which the Trustee shall have received notice from MetLife, Inc. that the number of Trust Shares held by the Trust is equal to 10 % or less of the number of issued and outstanding shares of Common Stock; or (ii) the date on which the last Trust Share shall have been withdrawn, distributed or exchanged. The Trust may be terminated earlier upon the first to occur of any of the following (each, an "Early Termination Event"):
 (i)on the 90th day after the date on which the Trustee receives written notice from MetLife, Inc., given at MetLife, Inc.'s discretion at any time, that the number of Trust Shares is 25 % or less of the number of issued and outstanding shares of Common Stock;
 (ii)on the date on which the Trustee receives written notice from MetLife, Inc. that the Board of Directors of MetLife, Inc. (the "Board") has determined, as a result of any amendment of, or change (including any announced prospective change) in the laws (or any regulations thereunder) of the United States or any State, Commonwealth or other political subdivision or authority thereof or therein, or any official administrative pronouncement or judicial decision interpreting or applying such law or regulation, or any changes in the facts or circumstances relating to the Trust, that maintaining the Trust is or is reasonably expected to become burdensome to MetLife, Inc. or the Beneficiaries;
 (iii)on the date on which any rights issued under a stockholder rights plan adopted by MetLife, Inc. and held by the Trust become separately tradable from the Trust Shares to which they relate; or
 (iv)on the date on which there is an entry of a final order for termination or dissolution of the Trust or similar relief by a court of competent jurisdiction.
 The Trust Agreement also contains a provision which would cause termination under certain circumstances in order to comply with legal rules governing the duration of trusts.
 Upon a Termination Event or an Early Termination Event, the Trustee and the Custodian will take such actions as may be necessary to wind up the Trust and distribute its assets to the Trust Beneficiaries pro rata in accordance with their respective Trust Interests, including the distribution in book-entry form to each Beneficiary, or as otherwise directed by such Beneficiary, together with the Beneficiary's proportionate share of all unpaid distributions and dividends and interest earned thereon, if applicable. The Trust Agreement provides that MetLife, Inc. may, at its discretion, offer to purchase such shares at the market price of the Common Stock at the time of the purchase.
 Pursuant to the Trust Agreement, the Trust is eligible to be terminated at MetLife, Inc.'s discretion, as the Trust Shares constituted 16.1 % of the issued and outstanding shares of Common Stock at December 31, 2023. As of December 31, 2023, MetLife, Inc. had not advised the Trustee of any intention to voluntarily terminate the Trust.

 Notes to the Financial Statements — (continued)
 1. Significant Accounting Policies (continued)

 Common Stock Repurchase Authorizations
 MetLife, Inc. announced that the Board authorized common stock repurchases as follows:

 Authorization Remaining at

 Announcement Date
 Authorization Amount
 December 31, 2023

 (In millions)

 May 25, 2023
 $
 1,000
 $
 1,000

 May 3, 2023
 $
 3,000
 $
 1,102

 May 4, 2022
 $
 3,000
 $
 —

 August 4, 2021
 $
 3,000
 $
 —

 Under these authorizations, MetLife, Inc. may purchase its Common Stock from the Trust, in the open market (including pursuant to the terms of a pre-set trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended) and in privately negotiated transactions. Common Stock repurchases are subject to the discretion of the Board and will depend upon MetLife, Inc.'s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of the Common Stock compared to management's assessment of the stock's underlying value, applicable regulatory approvals, and other legal and accounting factors. MetLife, Inc. did not repurchase any shares of Common Stock from the Trust during any of the years ended December 31, 2023, 2022 and 2021.
 For the years ended December 31, 2023, 2022 and 2021, MetLife, Inc. repurchased 50,269,483 shares, 49,732,851 shares and 72,296,518 shares under these repurchase authorizations for $ 3.1 billion, $ 3.3 billion and $ 4.3 billion, respectively.
 Equity Securities
 Equity securities, which are entirely comprised of Common Stock, are reported at their estimated fair value based on the quoted prices in active markets that are readily and regularly obtainable. As such, these securities are categorized as Level 1 (unadjusted quoted prices in active markets for identical assets) in three-level fair value hierarchy in accordance with fair value measurement guidance. Unrealized investment gains and losses on securities are recorded in the statements of operations and statements of changes in net assets. Realized gains and losses on sales of securities are determined on a first-in first-out basis.
 The Trust Agreement provides that regular cash dividends, if any, collected or received by the Trustee with respect to the Trust Shares shall be distributed by the Custodian semi-annually to the Beneficiaries within 90 days after receipt by the Trustee. Distributions of all other cash dividends shall be made by the Custodian to the Beneficiaries on the first business day following the 30th day after the Trust receives the dividends. Alternatively, the Trust Agreement provides that the Trustee may arrange with MetLife, Inc. for the direct payment by MetLife, Inc. of such cash dividends to the Beneficiaries. Historically, MetLife, Inc. has used the latter method. See "— Receivable from MetLife, Inc. and Dividends Payable to Trust Beneficiaries." The Trust Agreement further provides that pending such distribution, cash dividends (unless distributed directly by MetLife, Inc. to Beneficiaries) shall be invested by the Trustee in short-term obligations of or guaranteed by the United States, or any agency or instrumentality thereof, and in certificates of deposit of any bank or trust company having, at the time of the investment, a combined capital and surplus not less than $500,000,000. Dividends or other distributions in Common Stock will be allocated to the Beneficiaries in proportion to their Trust Interests and held by the Trustee as Trust Shares. Generally, all other distributions by MetLife, Inc. to its stockholders will be held and distributed by the Trustee to the Custodian and by the Custodian to the Beneficiaries in proportion to their Trust Interests within 60 days of receipt of such distribution by the Trustee, subject to limited exceptions. All security transactions are recorded on a trade date basis.
 Receivable from MetLife, Inc. and Dividends Payable to Trust Beneficiaries
 In accordance with the Trust Agreement, MetLife, Inc. distributes cash dividends directly to the Beneficiaries at the same time as the payment of dividends to MetLife, Inc.'s stockholders. In the event that dividends are undeliverable to the Beneficiaries, MetLife, Inc. retains such dividends until they are claimed by such Beneficiaries or escheated in accordance with applicable state law. Cash dividends that have been declared but are undeliverable to the Beneficiaries and the cash amounts of dividend checks that have not been cashed by the Beneficiaries have been recorded as a receivable from MetLife, Inc. and a liability of the Trust to such Beneficiaries.

 Notes to the Financial Statements — (continued)
 1. Significant Accounting Policies (continued)

 Income Tax
 As a grantor trust, the Trust is not subject to United States federal income taxes.

 2. Purchase and Sale Program
 Beneficiaries may instruct the program agent for the Purchase and Sale Program to withdraw their allocated shares from the Trust for sale through the Purchase and Sale Program. Under this program, 3,778,528; 3,637,360; and 4,233,165 Trust Interests were redeemed, which generated net realized investment gains of $ 186 million, $ 199 million and $ 202 million for the years ended December 31, 2023, 2022 and 2021, respectively. Beneficiaries allocated less than 1,000 shares of Common Stock under the Plan are also entitled to purchase in the Purchase and Sale Program additional shares, subject to a minimum of $ 250 per purchase (or such lesser amount that would cause the Beneficiary to hold the 1,000 maximum number of Trust Interests). Under this program, 17,194; 22,259; and 31,979 Trust Interests were issued for the years ended December 31, 2023, 2022 and 2021, respectively. The number of Trust Interests allocated to Beneficiaries will be adjusted for any shares of Common Stock purchased or sold in the Purchase and Sale Program such that the Trust Interests held by a Beneficiary will always equal the number of shares of Common Stock allocated to the Beneficiary.
 Beneficiaries may withdraw all, but generally not less than all, of their allocated shares of Common Stock from the Trust at any time by providing written notice to the Custodian. After the passage of sufficient time, unclaimed cash and Common Stock will be remitted as unclaimed property to the state of last known residence of the Beneficiary, as is the case with other types of unclaimed property. The schedule by which unclaimed property escheats varies by state, but is generally within three to five years of abandonment.

 3. Contingencies
 Litigation
 There is no pending or threatened litigation, claim or assessment against the Trust.

 4. Beneficiary Voting Rights
 The Trust Agreement provides the Trustee with directions as to the manner in which to vote, assent or consent the Trust Shares at all times during the term of the Trust. On all matters brought for a vote before the stockholders of MetLife, Inc., with the exception of a Beneficiary Consent Matter (as defined in the Trust Agreement), the Trustee will vote or abstain from voting in accordance with the recommendation given by the Board to its stockholders or, if no such recommendation is given, as directed by the Board. On all Beneficiary Consent Matters, the Trustee will vote all of the Trust Shares in favor of, in opposition to or abstain from the matter in the same ratio as the Trust Interests of the Beneficiaries that returned voting instructions to the Trustee indicated preferences for voting in favor of, in opposition to or abstaining from such matter. The Trust Agreement also contains provisions allowing Beneficiaries to instruct the Custodian to withdraw their allocated Trust Shares to participate in any tender or exchange offer for the Common Stock and to make any cash or share election, or perfect any dissenter's rights, in connection with a merger of MetLife, Inc.

 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
 None.

 Item 9A. Controls and Procedures
 Evaluation of Disclosure Controls and Procedures
 The Trustee, with the participation of Haley Owen, Assistant Vice President of Wilmington Trust Company, the Trustee of the Trust, has evaluated the effectiveness of the design and operation of the Trust's disclosure controls and procedures pursuant to Rule 13a-15(b) under the Exchange Act as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, Ms. Owen concluded that these disclosure controls and procedures were effective as of December 31, 2023.
 The Trustee and Ms. Owen, in making these determinations, have relied to the extent reasonable on information provided by MetLife, Inc. and the Custodian. There were no changes to the Trust's internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Trust's internal control over financial reporting.
 Management's Annual Report on Internal Control Over Financial Reporting
 The Trustee is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and 15(d)-15(f) under the Exchange Act. In fulfilling this responsibility, estimates and judgments by the Trustee are required to assess the expected benefits and related costs of control procedures. The objectives of internal control include providing the Trustee with reasonable, but not absolute, assurance that assets are safeguarded against loss from unauthorized use or disposition, and that transactions are executed in accordance with the Trustee's authorization and recorded properly to permit the preparation of financial statements in conformity with accounting principles generally accepted in the United States of America.
 The Trustee has evaluated the design and operating effectiveness of the Trust's internal control over financial reporting based on the criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
 In the opinion of the Trustee, the Trust maintained effective internal control over financial reporting as of December 31, 2023.

 Item 9B. Other Information
 Securities trading plans
 There are no directors or Section 16 officers (as defined in Rule 16a-1(f) of the Exchange Act) of the Trust.

 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 Item 10. Directors, Executive Officers and Corporate Governance
 There are no directors, executive officers or employees of the Trust. The Trustee of the Trust is Wilmington Trust Company. The Custodian of the Trust is Computershare Inc.
 The Trust has not adopted a code of ethics applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions because the Trust does not have any such officers.

 Item 11. Executive Compensation
 There are no directors or executive officers of the Trust.

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
 There are no directors or executive officers of the Trust. No person is the beneficial owner of more than five percent of the Trust Interests.
 The Trust has no equity compensation plans.

 Item 13. Certain Relationships and Related Transactions, and Director Independence
 There are no directors or executive officers of the Trust.

 Item 14. Principal Accountant Fees and Services
 Pursuant to the Trust Agreement, the independent auditor of MetLife, Inc. serves as the independent auditor of the Trust. Deloitte & Touche LLP ("Deloitte"), the independent auditor of MetLife, Inc., has served as the independent auditor of the Trust since 2000. Its knowledge of the Trust and its independence has enabled it to carry out audits of the Trust's financial statements with effectiveness and efficiency. Deloitte is a registered public accounting firm with the Public Company Accounting Oversight Board (United States) ("PCAOB") as required by the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley") and the Rules of the PCAOB.
 Under current legal requirements, the lead or concurring audit partner for MetLife, Inc. may not serve in that role for more than five consecutive fiscal years, and the Audit Committee of MetLife, Inc. (the "Audit Committee") ensures the regular rotation of the audit engagement team partners as required by law. The Chair of the Audit Committee, together with other members of the Audit Committee and management of MetLife, Inc., is actively involved in the selection process for the lead and concurring partners.
 Independent Auditor's Fees for 2023 and 2022
 The table below presents fees for professional services rendered by Deloitte for the audit of the Trust's annual financial statements, audit-related services, tax services and all other services for the years ended December 31, 2023 and 2022. All fees shown in the table were related to services that were approved by the Audit Committee.

 2023
 2022

 Audit fees (1)
 $
 58,500
 $
 58,500

 Audit-related fees
 $
 —
 $
 —

 Tax fees
 $
 —
 $
 —

 All other fees
 $
 —
 $
 —

 ____________
 (1)Fees for services to perform an audit in accordance with auditing standards of the PCAOB and services that generally only the Trust's independent auditor can reasonably provide, such as attest services and assistance with and review of documents filed with the SEC.

 Approval of Fees
 The Trust does not have an audit committee. The Audit Committee approves Deloitte's audit and non-audit services in advance as required under Sarbanes-Oxley and SEC rules. Before the commencement of each fiscal year, the Audit Committee appoints the independent auditor to perform pre-approved audit services and pre-approved audit-related, tax and other permitted non-audit services that MetLife, Inc. expects to be performed for the fiscal year, including for the Trust. The Audit Committee or a designated member of the Audit Committee to whom authority has been delegated may, from time to time, pre-approve additional audit and non-audit services to be performed by MetLife, Inc.'s independent auditor. Any pre-approval of services between Audit Committee meetings must be reported to the full Audit Committee at its next scheduled meeting.
 The Audit Committee is responsible for approving fees for the audit and for any audit-related, tax or other permitted non-audit services. If the audit, audit-related, tax and other permitted non-audit fees for a particular period or service exceed the amounts previously approved, the Audit Committee determines whether or not to approve the additional fees.

 Item 15. Exhibits and Financial Statement Schedules
 The following documents are filed as part of this report:
 1.Financial Statements
 The financial statements are listed in the Index to Financial Statements and Notes on page 11.
 2.Financial Statement Schedules
 3.Exhibits
 The exhibits are listed in the Exhibit Index on page 24.
 Item 16. Form 10-K Summary
 None.

 Exhibit Index

 (Note Regarding Reliance on Statements in Our Contracts: In reviewing the agreements included as exhibits to this Annual Report on Form 10-K, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the MetLife Policyholder Trust or the other parties to the agreements. The agreements contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and (i) should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; (iii) may apply standards of materiality in a way that is different from what may be viewed as material to investors; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the MetLife Policyholder Trust may be found elsewhere in this Annual Report on Form 10-K and its other public filings, which are available without charge through the SEC's website at www.sec.gov.)

 Incorporated by Reference

 Exhibit No.
 Description
 Form
 File Number
 Exhibit
 Filing Date
 Filed or Furnished
 Herewith

 3.1
 MetLife Policyholder Trust Agreement.

 S-1*
 333-91517
 10.12
 November 23, 1999

 3.2
 Amendment to MetLife Policyholder Trust Agreement.

 10-K*
 10.62
 February 27, 2013

 4.1.1
 Amended and Restated Certificate of Incorporation of MetLife, Inc.

 10-K*

 3.1
 March 1, 2017

 4.1.2
 Certificate of Retirement of Series B Contingent Convertible Junior Participating Non-Cumulative Perpetual Preferred Stock of MetLife, Inc., filed with the Secretary of State of Delaware on November 5, 2013.

 10-Q*
 3.6
 November 7, 2013

 4.1.3
 Certificate of Amendment of Amended and Restated Certificate of Incorporation of MetLife, Inc., dated April 29, 2015.

 8-K*
 3.1
 April 30, 2015

 4.1.4
 Certificate of Elimination of 6.500% Non-Cumulative Preferred Stock, Series B, of MetLife, Inc., filed with the Secretary of State of Delaware on November 3, 2015.

 10-Q*
 3.7
 November 5, 2015

 4.1.5
 Certificate of Amendment of Amended and Restated Certificate of Incorporation of MetLife, Inc., dated April 29, 2011.

 10-K*
 3.4
 March 1, 2017

 4.1.6
 Certificate of Designation, Preferences and Rights of Series A Junior Participating Preferred Stock of MetLife, Inc., filed with the Secretary of State of Delaware on April 7, 2000.

 10-K*
 3.2
 March 1, 2017

 4.1.7
 Certificate of Designations of Floating Rate Non-Cumulative Preferred Stock, Series A, of MetLife, Inc., filed with the Secretary of State of Delaware on June 10, 2005.

 10-K*
 3.3
 March 1, 2017

 4.1.8
 Certificate of Amendment of Amended and Restated Certificate of Incorporation of MetLife, Inc., dated October 23, 2017

 8-K*
 3.1
 October 24, 2017

 4.1.9
 Certificate of Designations of 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, of MetLife, Inc., filed with the Secretary of State of Delaware on March 21, 2018.

 8-K*
 3.1
 March 22, 2018

 4.1.10
 Certificate of Designations of 5.625% Non-Cumulative Preferred Stock, Series E, of MetLife, Inc., filed with the Secretary of the State of Delaware on May 31, 2018.

 8-K*
 3.1
 June 4, 2018

 4.1.11
 Certificate of Designations of 4.75% Non-Cumulative Preferred Stock, Series F, of MetLife, Inc. filed with the Secretary of the State of Delaware on January 8, 2020

 8-K*
 3.1
 January 9, 2020

 Incorporated by Reference

 Exhibit No.
 Description
 Form
 File Number
 Exhibit
 Filing Date
 Filed or Furnished
 Herewith

 4.1.12
 Certificate of Designations of 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, of MetLife, Inc., filed with the Secretary of the State of Delaware on September 9, 2020.

 8-K*
 3.1
 September 10, 2020

 4.1.13
 Certificate of Elimination of 5.250% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series C, of MetLife, Inc., filed with the Secretary of State of Delaware on June 29, 2021.

 8-K*
 3.1
 June 29, 2021

 4.2
 Amended and Restated By-Laws of MetLife, Inc., effective October 3, 2023.

 8-K*
 3.2
 October 5, 2023

 4.3
 Form of Certificate for Common Stock, par value $0.01 per share.

 S-1/A*
 333-91517
 4.1
 March 9, 2000

 4.4
 Form of Stock Certificate, Floating Rate Non-Cumulative Preferred Stock, Series A, of MetLife, Inc.

 8-A*
 99.6
 June 10, 2005

 4.5
 Form of Stock Certificate, 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, of MetLife, Inc.

 8-K*
 4.1
 March 22, 2018

 4.6
 Form of Stock Certificate, 5.625% Non-Cumulative Preferred Stock, Series E, of MetLife, Inc.

 8-K*
 4.1
 June 4, 2018

 4.7
 Form of Stock Certificate, 4.75% Non-Cumulative Preferred Stock, Series F, of MetLife, Inc.

 8-K*
 4.1
 January 9, 2020

 4.8
 Form of Stock Certificate, 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, of MetLife, Inc.

 8-K*
 4.1
 September 10, 2020

 4.9
 Description of Securities.

 X

 31.1
 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 X

 32.1
 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 X

 101.SCH
 X

 101.CAL
 X

 101.DEF
 X

 101.LAB
 X

 101.PRE
 X

 101.INS
 X

 X

 __________
 * Filed on behalf of MetLife, Inc.

 Signatures
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 METLIFE POLICYHOLDER TRUST

 By:
 Wilmington Trust Company, not in its individual capacity, but solely as trustee for the Trust

 By:
 /s/ Haley Owen

 Name: Haley Owen

 Title: Assistant Vice President

 Date: March 27, 2024